Using a new laser technique to remove bladder tumors
LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
This study is testing a new laser technique to see if it can safely and effectively remove bladder tumors in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Kansas Medical Center Academic / other |
| Locations | 1 site (Kansas City, Kansas) |
| Trial ID | NCT04979156 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of the SOLTIVE™ Thulium Super Pulse laser for en bloc resection of bladder tumors in patients at the University of Kansas Health System. The study follows standard pre-treatment evaluations and follow-up schedules, collecting prospective data on patients undergoing this procedure. The laser's advanced technology aims to improve precision and reduce complications during tumor removal. The study will assess the effectiveness and safety of this innovative approach compared to traditional methods.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with papillary bladder tumors that are 3 cm or smaller.
Not a fit: Patients with non-papillary lesions or those unwilling to undergo en bloc resection may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could lead to fewer complications and lower recurrence rates for bladder cancer patients.
How similar studies have performed: Previous studies have shown success with laser en bloc resection techniques, but the specific use of the SOLTIVE™ Thulium laser in this context is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients must be 18 years of age or older. 2. Patient presenting for resection of papillary bladder tumor visualized on cystoscopy 1. New bladder tumor 2. Recurrent tumors 3. Tumor \<3cm Exclusion Criteria: 1. Patient unwilling to undergo en bloc resection 2. Non papillary lesions/tumors
Where this trial is running
Kansas City, Kansas
- University of Kansas Medical Center — Kansas City, Kansas, United States (Recruiting)
Study contacts
- Principal investigator: Jeffrey Holzbeierlein — University of Kansas Medical Center
- Study coordinator: Jane Ledesma
- Email: jledesma2@kumc.edu
- Phone: 9135888721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.